nach oben

Drug Safety

Erschienen in:

01.09.2019 | Systematic Review

Fluoroquinolone Use and the Risk of Collagen-Associated Adverse Events: A Systematic Review and Meta-Analysis

verfasst von: Xinyu Yu, Ding-sheng Jiang, Jing Wang, Rui Wang, Taiqiang Chen, Kan Wang, Shiyi Cao, Xiang Wei

Erschienen in: Drug Safety | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

It has been suggested that fluoroquinolone antibiotics increase the risk of developing collagen-associated adverse events such as aortic dissection and aortic aneurysm. These are life-threatening emergencies that need to be prevented.

Objectives

We performed this systematic review to clarify the association between fluoroquinolones and three collagen-associated adverse events: aortic aneurysm or aortic dissection, retinal detachment, and tendon disorders.

Methods

We searched PubMed, Embase, and Scopus for observational studies up to January 2019. Cohort and case–control studies were included if they reported data on the risk of collagen-related adverse events associated with fluoroquinolone exposure versus no exposure. We assessed the quality of the included studies using the Newcastle–Ottawa Scale. Effect statistics were pooled using random-effects models. Sensitivity and subgroup analyses were performed to identify any source of heterogeneity.

Results

After screening 2729 citations, we included 22 observational studies (12 cohort studies and ten case–control studies) with 19,207,552 participants. Current use of fluoroquinolones was significantly associated with aortic aneurysm and aortic dissection (odds ratio [OR] 2.20; 95% confidence interval [CI] 1.92–2.52), tendon disorders (OR 1.89; 95% CI 1.53–2.33), and retinal detachment (sensitivity analysis, OR 1.25; 95% CI 1.01–1.53). Past fluoroquinolone use (> 30 and ≤ 365 days) was associated with retinal detachment (OR 1.27; 95% CI 1.09–1.47).

Conclusions

Fluoroquinolone use incurs a risk of developing three collagen-associated diseases (aortic aneurysm or aortic dissection, retinal detachment, and tendon disorders). Patients at an increased risk of collagen-associated diseases should not use fluoroquinolones unless no other options are available.

Nur mit Berechtigung zugänglich

Hicks LA, Taylor TH, Hunkler RJUS. Outpatient antibiotic prescribing, 2010. New Engl J Med. 2013;368(15):1461–2. https://doi.org/10.1056/NEJMc1212055.CrossRefPubMed

Pasternak B, Inghammar M, Svanstrom H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:k678. https://doi.org/10.1136/bmj.k678.CrossRefPubMedPubMedCentral

Kaleagasioglu F, Olcay E. Fluoroquinolone-induced tendinopathy: etiology and preventive measures. Tohoku J Exp Med. 2012;226(4):251–8. https://doi.org/10.1620/tjem.226.251.CrossRefPubMed

Redgrave LS, Sutton SB, Webber MA, Piddock LJV. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 2014;22(8):438–45. https://doi.org/10.1016/j.tim.2014.04.007.CrossRefPubMed

Akali AU, Niranjan NS. Management of bilateral Achilles tendon rupture associated with ciprofloxacin: a review and case presentation. J Plast Reconstr Aesthetic Surg. 2008;61(7):830–4. https://doi.org/10.1016/j.bjps.2006.08.005.CrossRef

Stinner DJ, Orr JD, Hsu JR. Fluoroquinolone-associated bilateral patellar tendon rupture: A case report and review of the literature. Mil Med. 2010;175(6):457–9. https://doi.org/10.7205/MILMED-D-09-00142.CrossRefPubMed

Shybut TB, Puckett ER. Triceps ruptures after fluoroquinolone antibiotics: a report of 2 cases. Sports Health. 2017;9(5):474–6. https://doi.org/10.1177/1941738117713686.CrossRefPubMedPubMedCentral

Tsai WC, Hsu CC, Chen CPC, Chang HN, Wong AMK, Lin MS, et al. Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type i collagen. J Orthop Res. 2011;29(1):67–73. https://doi.org/10.1002/jor.21196.CrossRefPubMed

Rampal S, Kaur R, Sethi R, Singh O, Sood N. Ofloxacin-associated retinopathy in rabbits: role of oxidative stress. Hum Exp Toxicol. 2008;27(5):409–15. https://doi.org/10.1177/0960327108092295.CrossRefPubMed

10.

Van der Linden PD, Sturkenboom MCJM, Herings RMC, Leufkens HGM, Stricker BHC. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. Br Med J. 2002;324(7349):1306–7.CrossRef

11.

Van der Linden PD, Sturkenboom MCJM, Herings RMC, Leufkens HMG, Rowlands S, Stricker BHC. Increased risk of Achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch Intern Med. 2003;163(15):1801–7. https://doi.org/10.1001/archinte.163.15.1801.CrossRefPubMed

12.

Seeger JD, West WA, Fife D, Noel GJ, Johnson LN, Walker AM. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Pharmacoepidemiol Drug Saf. 2006;15(11):784–92. https://doi.org/10.1002/pds.1214.CrossRefPubMed

13.

Van der Linden PD, Van de Lei J, Nab HW, Knol A, Stricker BHC. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol. 1999;48(3):433–7. https://doi.org/10.1046/j.1365-2125.1999.00016.x.CrossRefPubMedPubMedCentral

14.

Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J. 2002;21(6):525–9. https://doi.org/10.1097/00006454-200206000-00009.CrossRefPubMed

15.

Sode J, Obel N, Hallas J, Lassen A. Use of fluroquinolone and risk of Achilles tendon rupture: a population-based cohort study. Eur J Clin Pharmacol. 2007;63(5):499–503. https://doi.org/10.1007/s00228-007-0265-9.CrossRefPubMed

16.

Hori K, Yamakawa K, Yoshida N, Ohnishi K, Kawakami J. Detection of fluoroquinolone-induced tendon disorders using a hospital database in Japan. Pharmacoepidemiol Drug Saf. 2012;21(8):886–9. https://doi.org/10.1002/pds.3285.CrossRefPubMed

17.

Morales DR, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X. Relative and absolute risk of tendon rupture with fluoroquinolone and concomitant fluoroquinolone/corticosteroid therapy: population-based nested case-control study. Clin Drug Investig. 2019;39(2):205–13. https://doi.org/10.1007/s40261-018-0729-y.CrossRefPubMed

18.

Tanne JH. FDA adds “black box” warning label to fluoroquinolone antibiotics. BMJ. 2008;337:a816. https://doi.org/10.1136/bmj.a816.CrossRefPubMed

19.

Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. Oral fluoroquinolones and the risk of retinal detachment. J Am Med Assoc. 2012;307(13):1414–9. https://doi.org/10.1001/jama.2012.383.CrossRef

20.

Pasternak B, Svanström H, Melbye M, Hviid A. Association between oral fluoroquinolone use and retinal detachment. J Am Med Assoc. 2013;310(20):2184–90. https://doi.org/10.1001/jama.2013.280500.CrossRef

21.

Choi SY, Lim HA, Yim HW, Park YH. Administration of oral fluoroquinolone and the risk of rhegmatogenous retinal detachment: a nationwide population-based study in Korea. PLoS One. 2018;13(4):e0195563. https://doi.org/10.1371/journal.pone.0195563.CrossRefPubMedPubMedCentral

22.

Eftekhari K, Ghodasra DH, Haynes K, Chen J, Kempen JH, Vanderbeek BL. Risk of retinal tear or detachment with oral fluoroquinolone use: a cohort study. Pharmacoepidemiol Drug Saf. 2014;23(7):745–52. https://doi.org/10.1002/pds.3623.CrossRefPubMedPubMedCentral

23.

Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open. 2015;5(11):e010077. https://doi.org/10.1136/bmjopen-2015-010077.CrossRefPubMedPubMedCentral

24.

Lee CC, Gabriel Lee MT, Chen YS, Lee SH, Chen YS, Chen SC, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med. 2015;175(11):1839–47. https://doi.org/10.1001/jamainternmed.2015.5389.CrossRefPubMed

25.

Pouzaud F, Bernard-Beaubois K, Thevenin M, Warnet JM, Hayem G, Rat P. In vitro discrimination of fluoroquinolones toxicity on tendon cells: involvement of oxidative stress. J Pharmacol Exp Ther. 2004;308(1):394–402. https://doi.org/10.1124/jpet.103.057984.CrossRefPubMed

26.

Baugé C, Leclercq S, Conrozier T, Boumediene K. TOL19-001 reduces inflammation and MMP expression in monolayer cultures of tendon cells. BMC Complement Altern Med. 2015;15(1):217. https://doi.org/10.1186/s12906-015-0748-7.CrossRefPubMedPubMedCentral

27.

Kumbhar GB, Khan AM, Rampal S. Evaluation of gatifloxacin for its potential to induce antioxidant imbalance and retinopathy in rabbits. Hum Exp Toxicol. 2015;34(4):372–9. https://doi.org/10.1177/0960327114530743.CrossRefPubMed

28.

Belavic JM. Fluoroquinolone-induced tendinopathy. Nurse Pract. 2009;34(1):17–8. https://doi.org/10.1097/01.NPR.0000343751.83969.1b.CrossRefPubMed

29.

Fife D, Zhu V, Voss E, Levy-Clarke G, Ryan P. Exposure to oral fluoroquinolones and the risk of retinal detachment: retrospective analyses of two large healthcare databases. Drug Saf. 2014;37(3):171–82. https://doi.org/10.1007/s40264-014-0138-y.CrossRefPubMedPubMedCentral

30.

Kuo SC, Chen YT, Lee YT, Fan NW, Chen SJ, Li SY, et al. Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study. Clin Infect Dis. 2014;58(2):197–203. https://doi.org/10.1093/cid/cit708.CrossRefPubMed

31.

Corrao G, Zambon A, Bertù L, Mauri A, Paleari V, Rossi C, et al. Evidence of tendinitis provoked by fluoroquinolone treatment a case-control study. Drug Saf. 2006;29(10):889–96. https://doi.org/10.2165/00002018-200629100-00006.CrossRefPubMed

32.

Moher D, Liberati AF, Tetzlaff J, Tetzlaff JF, Altman DG, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. (1539-3704 (Electronic)).

33.

Hartling L, Milne A, Hamm MP, Vandermeer B, Ansari M, Tsertsvadze A, et al. Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers. J Clin Epidemiol. 2013;66(9):982–93. https://doi.org/10.1016/j.jclinepi.2013.03.003.CrossRefPubMed

34.

Singh S, Nautiyal A. Aortic dissection and aortic aneurysms associated with fluoroquinolones: a systematic review and meta-analysis. Am J Med. 2017;130(12):1449. https://doi.org/10.1016/j.amjmed.2017.06.029.CrossRefPubMed

35.

Chui CSL, Wong ICK, Wong LYL, Chan EW. Association between oral fluoroquinolone use and the development of retinal detachment: a systematic review and meta-analysis of observational studies. J Antimicrob Chemother. 2015;70(4):971–8. https://doi.org/10.1093/jac/dku507.CrossRefPubMed

36.

Alves C, Penedones A, Mendes D, Batel Marques F. A systematic review and meta-analysis of the association between systemic fluoroquinolones and retinal detachment. Acta Ophthalmol. 2016;94(5):e251–9. https://doi.org/10.1111/aos.12931.CrossRefPubMed

37.

Jupiter DC, Fang X, Ashmore Z, Shibuya N, Mehta HB. The relative risk of achilles tendon injury in patients taking quinolones. Pharmacotherapy. 2018;38(9):878–87. https://doi.org/10.1002/phar.2162.CrossRefPubMed

38.

Etminan M, Maberley DAL. Improving reporting quality in ophthalmologic observational studies that use big data: the case of retinal detachment associated with fluoroquinolone use. (2168-6173 (Electronic)).

39.

FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. https://www.fda.gov/Drugs/DrugSafety/ucm628753.htm.

40.

Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. https://www.ema.europa.eu/en/documents/press-release/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone_en.pdf. Accessed 1 Mar 2019.

41.

Corps AN, Harrall RL, Curry VA, Fenwick SA, Hazleman BL, Riley GP. Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1beta in human tendon-derived cells. A potential mechanism of fluoroquinolone-induced tendinopathy. Arthritis Rheum. 2002;46(11):3034–40. https://doi.org/10.1002/art.10617.CrossRefPubMed

42.

LeMaire SA, Zhang L, Luo W, Ren P, Azares AR, Wang Y, et al. Effect of ciprofloxacin on susceptibility to aortic dissection and rupture in mice. JAMA Surg. 2018;153(9):e181804. https://doi.org/10.1001/jamasurg.2018.1804.CrossRefPubMedPubMedCentral

43.

Amin M, Pushpakumar S, Muradashvili N, Kundu S, Tyagi SC, Sen U. Regulation and involvement of matrix metalloproteinases in vascular diseases. Front Biosci (Landmark edition). 2016;21:89–118.CrossRefPubMedCentral

44.

Feltgen N, Walter P. Rhegmatogenous retinal detachment–an ophthalmologic emergency. Dtsch Arztebl Inter. 2014;111(1–2):12–22. https://doi.org/10.3238/arztebl.2014.0012.CrossRef

45.

Baek YH, Park SJ, Jeong S, Oh IS, Jeong HE, Park KH, et al. Signal detection between fluoroquinolone use and the risk of rhegmatogenous retinal detachment: sequence symmetry analysis using nationwide South Korean healthcare database between 2004 and 2015. Clin Drug Investig. 2018. https://doi.org/10.1007/s40261-018-0708-3.CrossRefPubMed

Titel: Fluoroquinolone Use and the Risk of Collagen-Associated Adverse Events: A Systematic Review and Meta-Analysis
verfasst von: Xinyu Yu
Ding-sheng Jiang
Jing Wang
Rui Wang
Taiqiang Chen
Kan Wang
Shiyi Cao
Xiang Wei
Publikationsdatum: 01.09.2019
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 9/2019
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.1007/s40264-019-00828-z

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Fluoroquinolone Use and the Risk of Collagen-Associated Adverse Events: A Systematic Review and Meta-Analysis

Abstract

Introduction

Objectives

Methods

Results

Conclusions

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Introduction

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers

Auto-Generated Physiological Chain Data for an Ontological Framework for Pharmacology and Mechanism of Action to Determine Suspected Drugs in Cases of Dysuria

Evaluation of Use of Technologies to Facilitate Medical Chart Review

Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case–Control Study

Prevalence, Safety and Long-Term Retention Rates of Biologics in Hong Kong from 2001 to 2015

Evaluation of Potential Drug–Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis